New Covid vaccines are on the way as 'Eris' variant rises

investing.com:

By Michael Erman

NEW YORK (Reuters) — A new COVID vaccine is due out next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from «Eris», a variant of the Omicron form of the coronavirus, rise around the country.

Some public health experts hope that Americans will welcome the new shot as they would a flu jab. But demand for the vaccine has dropped sharply since 2021 when it first became available and more than 240 million people in the U.S., or 73% of the population, received at least one shot.

In the fall of 2022, by which time most people had either had the COVID virus or the vaccine, fewer than 50 million people got the shots.

Healthcare providers and pharmacies such as CVS Health (NYSE:CVS) will start next month to offer the shot, updated to fight the Omicron version of the virus that has been dominant since last year.

They will be fighting declining concern about the virus, as well as fatigue and skepticism about the merits of this vaccine, Kaiser Family Foundation Director of Survey Methodology Ashley Kirzinger said.

«Public health officials, if they want to see a majority of adults get these annual vaccines, they're going to have to make the case to the American public that COVID isn't over and it still poses a risk to them,» Kirzinger said.

The top reason vaccinated people gave in KFF surveys earlier this year for eschewing annual shots was they believed they had protection from the virus because of previous shots or infections, she said.

COVID-19 vaccine makers have pared back expectations for this fall's vaccination campaign, with Pfizer (NYSE:PFE) – the largest maker of mRNA shots with BioNTech – recently warning that it might need to cut jobs if it does